Journal of International Oncology››2014,Vol. 41››Issue (2): 107-109.doi:10.3760/cma.j.issn.1673-422X.2014.02.009
Previous ArticlesNext Articles
Yu Xiao, Wang Yanming
Received:
2013-10-08Revised:
2013-12-04Online:
2014-02-08Published:
2014-01-26Contact:
Wang Yanming E-mail:ymwang64@163.comYu Xiao, Wang Yanming. Cyberknife treatment for nonsmall cell lung cancer[J]. Journal of International Oncology, 2014, 41(2): 107-109.
[1] Seisen T, Drouin SJ, Phé V, et al. Current role of imageguided robotic radiosurgery (Cyberknife()) for prostate cancer treatment[J]. BJU Int, 2013, 111(5): 761-766. [2] Bibault JE, Prevost B, Dansin E, et al. Imageguided robotic stereotactic radiation therapy with fiducialfree tumor tracking for lung cancer[J]. Radiat Oncol, 2012, 7: 102. [3] Onishi H, Araki T. Stereotactic body radiation therapy for stage Ⅰ nonsmallcell lung cancer: a historical overview of clinical studies[J]. Jpn J Clin Oncol, 2013, 43(4): 345-350. [4] Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ nonsmall cell lung cancer: updated results of 257 patients in a Japanese multiinstitutional study[J]. J Thorac Oncol, 2007, 2(7 Suppl 3): S94-100. [5] van Baardwijk A, Tomé WA, van Elmpt W, et al. Is highdose stereotactic body radiotherapy (SBRT) for stage Ⅰ nonsmall cell lung cancer (NSCLC) overkill? A systematic review[J]. Radiother Oncol, 2012, 105(2): 145-149. [6] Guckenberger M, Wulf J, Mueller G, et al. Doseresponse relationship for imageguided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation[J]. Int J Radiat Oncol Biol Phys, 2009, 74(1): 47-54. [7] Zimmermann F, Wulf J, Lax I, et al. Stereotactic body radiation therapy for early nonsmall cell lung cancer[J]. Front Radiat Ther Oncol, 2010, 42: 94-114. [8] Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ nonsmallcell lung cancer patients treated with stereotactic body radiotherapy[J]. J Clin Oncol, 2009, 27(20): 3290-3296. [9] Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage Ⅰ nonsmallcell lung cancer: can SBRT be comparable to surgery?[J]. Int J Radiat Oncol Biol Phys, 2011, 81(5): 13521358. [10] van der Voort van Zyp NC, Prévost JB, Hoogeman MS, et al. Stereotactic radiotherapy with realtime tumor tracking for nonsmall cell lung cancer: clinical outcome[J]. Radiother Oncol, 2009, 91(3): 296-300. [11] Bonnette P. Chemoradiotherapy before surgery in stage Ⅲ nonsmallcell lung cancer[J]. Rev Mal Respir, 2013, 30(2): 105-114. [12] Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm[J]. Int J Radiat Oncol Biol Phys, 2009, 73(2): 442-448. [13] Whyte RI. Stereotactic radiosurgery for lung tumors[J]. Semin Thorac Cardiovasc Surg, 2010, 22(1): 59-66. [14] Pennathur A, Abbas G, Schuchert MJ, et al. Imageguided radiofrequency ablation for the treatment of earlystage nonsmall cell lung neoplasm in highrisk patients[J]. Semin Thorac Cardiovasc Surg, 2010, 22(1): 53-58. [15] Brown WT, Wu X, Fayad F, et al. Application of robotic stereotactic radiotherapy to peripheral stage Ⅰ nonsmall cell lung cancer with curative intent[J]. Clin Oncol (R Coll Radiol), 2009, 21(8): 623-631. [16] Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in earlystage nonsmallcell lung cancer: clinical implications[J]. Radiother Oncol, 2010, 94(1): 1-11. [17] Reck M, Heigener DF, Mok T, et al. Management of nonsmallcell lung cancer: recent developments[J]. Lancet, 2013, 382(9893): 709-719. [18] Saadeddin A. Radiotherapy for NSCLC: review of conventional and new treatment techniques[J]. J Infect Public Health, 2012, 5 Suppl 1: S45-49. [19] Dieterich S, Pawlicki T. Cyberknife imageguided delivery and quality assurance[J]. Int J Radiat Oncol Biol Phys, 2008, 71(1 Suppl):S126-130. [20] Lartigau E, Mirabel X, Prevost B, et al. Extracranial stereotactic radiotherapy: preliminary results with the CyberKnife[J]. Onkologie, 2009, 32(4): 209-215. [21] Prevost JB, Voet P, Hoogeman M, et al. Fourdimensional stereotactic radiotherapy for early stage nonsmall cell lung cancer: a comparative planningstudy[J]. Technol Cancer Res Treat, 2008, 7(1): 27-33. [22] Murphy MJ. Intrafraction geometric uncertainties in frameless imageguided radiosurgery[J]. Int J Radiat Oncol Biol Phys, 2009, 73(5): 1364-1368. [23] McCammon R, Schefter TE, Gaspar LE, et al. Observation of a dosecontrolrelationship for lung and liver tumors after stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2009, 73(1): 112-118. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[4] | Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[5] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[6] | Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42. |
[7] | Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552. |
[8] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[9] | Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376. |
[10] | Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2023 version)[J]. Journal of International Oncology, 2023, 50(4): 193-201. |
[11] | Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230. |
[12] | Shi Xaioqi, Wang Hongyan.Research progress on the interaction between gut microbiota and radiation enteritis[J]. Journal of International Oncology, 2023, 50(4): 244-247. |
[13] | Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun.Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases[J]. Journal of International Oncology, 2023, 50(3): 138-143. |
[14] | Huang Huayu, Gong Hongyun, Song Qibin.Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy[J]. Journal of International Oncology, 2023, 50(2): 102-106. |
[15] | Cao Xiaohui, Yu Hong, Li Wanhu.Application of CT-based radiomics analysis in predicting and identifying of treatment-associated pneumonitis[J]. Journal of International Oncology, 2023, 50(2): 107-111. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||